PLoS ONE · 2017 · 12 citations · 38 references
MedicineCardiologyRadiologyBiomedical ImagingCardiovascular PharmacotherapyUltrasonographyAortic ImagingAtherosclerosis PharmacotherapyCardiovascular ImagingContrast-enhanced UltrasonographyContrast-enhanced UltrasoundHemodynamicsAtherosclerotic Plaque CharacterizationAtherosclerotic Plaque ImagingAtherosclerotic ProgressionHeart RateIvabradine TherapyPlaque VulnerabilityT1-weighted ImagingVulnerable Plaque Assessment
OBJECTIVE: To investigate the effect of a heart rate (HR) lowering agent (Ivabradine) on features of atherosclerotic plaque vulnerability with magnetic resonance imaging (MRI), ultrasound imaging, and histology. APPROACH AND RESULTS: Atherosclerosis was induced in the abdominal aorta of 19 rabbits. Nine rabbits were treated with Ivabradine (17 mg/kg/day) during the entire study period. At week 14, imaging was performed. Plaque size was quantified on contrast-enhanced T1-weighted MR images. Microvascular flow, density, and permeability was studied with dynamic contrast-enhanced MRI. Plaque biomechanics was studied by measuring the aortic distension with ultrasound. After, animals were sacrificed and histology was performed. HR was reduced by 16% (p = 0.026) in Ivabradine-treated animals. No differences in absolute and relative vessel wall beat-to-beat distension were found, but due to the reduction in HR, the frequency of the biomechanical load on the plaque was reduced. Plaque size (MR and histology) was similar between groups. Although microvessel density (histology) was similar between groups, AUC and Ktrans, indicative for plaque microvasculature flow, density, and permeability, were decreased by 24% (p = 0.029) and 32% (p = 0.037), respectively. Macrophage content (relative RAM11 positive area) was reduced by 44% (p<0.001) on histology in Ivabradine-treated animals. CONCLUSIONS: HR lowering treatment with Ivabradine in an atherosclerotic rabbit model is associated with a reduction in vulnerable plaque features. The current study suggests that HR reduction may be beneficial for inducing or maintaining a more stable plaque phenotype.
38
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Karl Swedberg, Michel Komajda, Michael Böhm et al. · The Lancet · 2010 · 2.6K citations · Full text
Medicine, Cardiology, Pharmacology +11
Association Between Arterial Stiffness and Atherosclerosis
Nicole M. van Popele, Diederick E. Grobbee, Michiel L. Bots et al. · Stroke · 2001 · 1.1K citations
Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure
Kim Fox, Ian Ford, Philippe Gabríel Steg et al. · New England Journal of Medicine · 2014 · 482 citations · Full text
Assessment of the distensibility of superficial arteries
A.P.G. Hoeks, Peter J. Brands, F. A. M. Smeets et al. · Ultrasound in Medicine & Biology · 1990 · 477 citations
Judith C. Sluimer, Jean‐Marie Gasc, J.L. van Wanroij et al. · Journal of the American College of Cardiology · 2008 · 460 citations · Full text
Medicine, Cardiology, Cell Biology +15